Kinase inhibitors

Patent metadata

Field	Value
Publication number	US-10125100-B2
Application number	US-201715604258-A
Country	US
Kind code	B2
Filing date	May 24, 2017
Priority date	Oct 1, 2014
Publication date	Nov 13, 2018
Grant date	Nov 13, 2018

Abstract

There are provided compounds of formulas III and VIIa:

or a salt or protected derivative thereof, wherein Z 2 represents a structural fragment of formula V,

wherein R 1A to R 1E , R 2 to R 4 , R 5a , L and X 1 to X 3 have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

First claim

What is claimed is:

1. A compound of
formula III,

or a salt or protected derivative of said compound of formula III, wherein Z 2 represents a structural fragment of formula V:

wherein
R 2 and R 3 , together with the C-atoms to which they are attached, form a fused phenyl or pyridyl ring, which latter two rings are optionally substituted by one or more substituents selected from C 1-3 alkyl, C 1-3 haloalkyl, cyano and halo,

or one of R 2 and R 3 represents H, halo, cyano, C 1-3 alkyl or C 1-3 haloalkyl and the other independently represents halo, cyano, C 1-3 alkyl or C 1-3 haloalkyl,
or R 2 and R 3 together combine to form C 3-5 alkylene or C 3-5 alkenylene, which latter two groups are optionally substituted by one or more substituents selected from C 1-3 alkyl, C 1-3 haloalkyl, cyano and halo;
X 1 represents N or CH;
L represents a direct bond or C 1-2 alkylene;
X 2 represents CR Z or N;
X 3 represents CR 5b or N;
R Z represents H, halo, cyano, hydroxy, C 1-3 alkyl or C 1-3 alkoxy, which latter two groups are optionally substituted by one or more halo atoms;
R 4 represents
-Q 1 -[C(R 6c )(R 6d )—(CH 2 ) 0-1 CH 2 —Z] 1-12 —CH 2 (CH 2 ) 0-1 CH 2 —R 6a ,
-Q 2 -C(R 6c )(R 6d )—[C 1-5 alkylene]-R 6a , which C 1-5 alkylene group is optionally substituted by oxo and/or by one or more R 6e ,
-Q 3 -[C 1-4 alkylene] 0-1 -Het x1 , which C 1-4 alkylene group is optionally substituted by oxo and/or by one or more R 6e and which Het x1 group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, C 3-6 cycloalkyl, C 1-3 alkoxy and —[C(O)] 0-1 —C 1-4 alkyl, the C 1-4 alkyl part of which latter group is optionally substituted by one or more R 6e ,
-Q 22 -[C 1-4 alkylene] 0-1 -phenyl, which C 1-4 alkylene group is optionally substituted by oxo and/or by one or more R 6e , and which phenyl group is substituted by [C(O)] 0-1 —C 1-4 alkyl, the C 1-4 alkyl part of which latter group is optionally substituted by one or more R 6e , and which phenyl group is optionally further substituted by one or more substituents selected from halo, hydroxy, oxo, C 3-6 cycloalkyl and C 1-3 alkoxy,
—S(O) p R 6b ,
—[C 1-4 alkylene] 0-1 -CO 2 H,
Het x2 which Het x2 group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, C 1-3 alkyl and C 1-3 alkoxy,
—COR 6b ,
—CH 2 OH,
—CH 2 OP(O)(OH) 2 or
-Q 4 -P(O)(OR 9 )(R 7 );

Z represents, independently upon each occurrence, O, C(O)N(R 8 ) or N(R 8 )C(O);
R 5a and R 5b independently represent C 1-3 alkoxy or C 1-3 alkyl, which latter two groups are optionally substituted by one or more halo atoms, or R 5a and R 5b independently represent —N(R e )(R f ), C 2-3 alkynyl, H, cyano, —C(O)NH 2 , hydroxy, halo or —S(O) 0-2 —C 1-3 alkyl;
R 6a represents OR 7a , —S(O) 0-2 R 7aa , N(R 7b )R 7c or CO 2 H;
R 6b represents C 1-8 alkyl, C 3-8 cycloalkyl, phenyl, Het 1 or Het 2 , which latter five groups are optionally substituted by one or more substituents selected from halo, hydroxy, —OP(O)(OH) 2 , C 1-3 alkyl, C 1-3 alkoxy, —C 1-3 alkylene-R 6e and CO 2 H,
or R 6b represents —C 1-4 alkylene-Het 3 , which Het 3 group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, C 3-6 cycloalkyl, C 1-3 alkoxy and —[C(O)] 0-1 —C 1-3 alkyl, which C 1-3 alkyl group is optionally substituted by one or more R 6e ,
or, when p is 1 or 2, R 6b may alternatively represent OH,
or, when p is 2, R 6b may alternatively represent —N(R 7b )R 7c or —N(R 7b )—C(O)—R 7c ;
R 6e represents, independently upon each occurrence, halo, hydroxy, —OP(O)(OH) 2 , C 1-3 alkoxy, —N(R g )(R h ) or —CO 2 H;
R 7a to R 7c independently represent H or C 1-4 alkyl optionally substituted by one or more halo atoms or by —CO 2 H,
or R 7a represents P(O)(OH) 2 or Het 3 , which latter group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, C 3-6 cycloalkyl, C 1-3 alkoxy and —[C(O)] 0-1 —C 1-3 alkyl, which C 1-3 alkyl group is optionally substituted by one or more R 6e ,
or R 7b and/or R 7c represents —[C a alkylene]-[C b alkylene]-OR 7d ,
or R 7b and R 7c together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which R 7b and R 7c are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 hydroxyalkyl;
a and b independently represent an integer selected from 1, 2 and 3, wherein the sum of a and b is 2, 3 or 4;
R 7d represents H or C 1-4 alkyl optionally substituted by one or more halo atoms;
R 7aa represents —C(R 7d )(R 7e )—C 1-3 alkylene-OH or C 1-4 alkyl optionally substituted by one or more halo atoms or by —CO 2 H;
Q 1 , Q 2 , Q 22 and Q 3 independently represent —C(O)N(R 8 )—, —O— or —S(O) 2 N(R 8 )—, or Q 1 , Q 2 and Q 22 independently represent S(O) q ;
Q 4 represents a direct bond or C 1-3 alkylene;
n, m, p and q independently represent 0, 1 or 2;
R 6c , R 6d , R e , R f , R g , R h and R 8 independently represent H or methyl,
or R 6c and R 6d independently represent hydroxymethyl;
R 7 represents H, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, C 3-7 cycloalkyl or phenyl, which latter four groups are optionally substituted by one or more substituents selected from halo, OH, C 1-3 alkyl and C 1-3 alkoxy;
R 9 represents H or C 1-4 alkyl, which latter group is optionally substituted by one or more halo atoms or by phenyl, which phenyl group is optionally substituted by one or more substituents selected from halo, OH, C 1-3 alkyl and C 1-3 alkoxy;
Het x1 and Het x2 independently represent Het 1a or Het 3 ;
Het 1 and Het 1a represent, independently upon each occurrence, a 5- or 6-membered heterocyclic group that is fully aromatic, which group contains one or more heteroatoms selected from N, O and S; and
Het 2 and Het 3 represent, independently upon each occurrence, a 4- to 9-membered heterocyclic group that is fully saturated or partially unsaturated, and is monocyclic or is fused or bridged bicyclic, which group contains one or more heteroatoms selected from N, O and S, wherein said protected derivative is a compound in which:
(a) a H-atom of the NH 2 group of formula Ill is replaced by:
R′—C(O)—, wherein R′ is H, C 1-8 alkyl, phenyl or benzyl, which latter two groups are optionally substituted by one or more groups selected from halo, hydroxy, methyl and methoxy, or
R″—O—C(O)—, wherein R″ is tert-butyl, phenyl, benzyl or fluorenyl, which latter three groups are optionally substituted by one or more groups selected from halo, hydroxy, methyl and methoxy; and/or

(b) when R 4 represents —CO 2 H, said —CO 2 H group is protected as a C 1-8 alkyl ester.

2. A compound of
formula III, or a salt or protected derivative thereof, as claimed in claim 1 , wherein said compound or protected derivative is
methyl 4-((4-((4-aminonaphthalen-1-yl)oxy)pyridin-2-yl)amino)-2-methoxybenzoate or
methyl 4-((4-((4-((tert-butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyridin-2-yl)amino)-2-methoxybenzoate.

3. A compound of formula VIIa,

or a salt of said compound of formula VIIa, wherein
Q X represents —[C 1-4 alkylene]

Assignees

• Respivert Ltd
• Topivert Pharma Ltd

Inventors

• Baker Thomas Matthew
• Fyfe Matthew Colin Thor
• Jones Geraint
• Thom Stephen Malcolm

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title